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Histone deacetylase inhibitors (HDACi) can elicit a range of bio-
logical responses that affect tumor growth and survival, including
inhibition of cell cycle progression, induction of tumor cell-selective
apoptosis, suppression of angiogenesis, and modulation of im-
mune responses, and show promising activity against hematolog-
ical malignancies in clinical trials. Using the E-myc model of B cell
lymphoma, we screened tumors with defined genetic alterations in
apoptotic pathways for therapeutic responsiveness to the HDACi
vorinostat. We demonstrated a direct correlation between induc-
tion of tumor cell apoptosis in vivo and therapeutic efficacy.
Vorinostat did not require p53 activity or a functional death
receptor pathway to kill E-myc lymphomas and mediate a ther-
apeutic response but depended on activation of the intrinsic
apoptotic pathway with the proapoptotic BH3-only proteins Bid
and Bim playing an important role. Our studies provide important
information regarding the mechanisms of action of HDACi that
have broad implications regarding stratification of patients receiv-
ing HDACi therapy alone or in combination with other anticancer
agents.
BH3-only proteins  Bid  Bim  vorinostat
H istone deacetylase inhibitors (HDACi) are a class of anti-cancer agents currently being tested as therapies for hema-
tological malignancies and solid tumors (1). The anticancer
activities of these agents may involve one or more biological
effects, including induction of tumor cell differentiation, inhi-
bition of angiogenesis, modulation of immune responses, and
apoptosis (2). Transformed cell lines may respond to HDACi by
undergoing apoptosis accompanied by cleavage and activation of
the proapoptotic Bcl-2 family member Bid, loss of mitochondrial
outer membrane potential (MOMP, m), reactive oxygen
species (ROS) production, cytochrome c release, caspase acti-
vation,andDNAfragmentation(3–7).Overexpressionofantiapo-
ptotic Bcl-2 inhibited HDACi-induced apoptosis in vitro, indi-
cating an important role for the mitochondrial apoptotic
pathway in the tumoricidal action of HDACi (4, 7, 8). A role for
the extrinsic apoptotic pathway has been proposed on the basis
of studies showing that various TNF receptors and their ligands
are transcriptionally activated after HDACi treatment that
correlates with HDACi-induced apoptosis (2, 9). The clinical
relevance of data obtained from in vitro systems may be limited.
It is not known whether the therapeutic effects of HDACi
depend on their intrinsic effects on tumor cell growth and/or
survival, their indirect effects (i.e., immune modulation, antian-
giogenesis), or a combination of these effects.
The E-myc model of B cell lymphoma has been successfully
used to characterize in vivo responses to anticancer drugs (10,
11). A key feature of the model is that defined cancer genotypes
can be created by crossing E-myc mice with gene-targeted
knockout mice, or by retrovirally transducing primary lympho-
mas to overexpress a gene of interest. Using this model, we
performed a candidate screen to identify the apoptotic proteins
and pathways necessary for HDACi activity. HDACi rapidly
induced death of E-myc lymphoma cells mediated by the
intrinsic apoptotic process. When transplanted into mice, E-
myc lymphomas were sensitive to the HDAC inhibitor vorinostat
[suberoylanilide hydroxamic acid (SAHA)] (12), leading to
prolonged survival compared with control-treated mice. The
efficacy of vorinostat against E-myc lymphomas was p53-
independent and did not require a functional death receptor
apoptotic pathway. E-myc lymphomas overexpressing Bcl-2 or
Bcl-XL were resistant to vorinostat-induced apoptosis but still
underwent a block in cell cycle progression at the G1/S transition.
Vorinostat conferred no therapeutic effect against E-myc/Bcl-2
or E-myc/Bcl-XL lymphomas, demonstrating a direct link be-
tween the ability of this agent to induce apoptosis and thera-
peutic outcome. Constraining the cellular apoptotic program by
genetic targeting of the BH3-only proapoptotic proteins Bid or
Bim impinged on in vivo sensitivity to vorinostat and suppressed
the therapeutic effect of the compound. Thus, we have identified
key apoptotic molecules that not only control sensitivity of
lymphoma cells to HDACi in in vivo assays but also determine
therapeutic outcome.
Results
E-myc B Cell Lymphomas Are Sensitive to HDACi in Vitro. Cultured
E-myc lymphoma cells were incubated with various concen-
trations of the HDACis vorinostat, oxamflatin, and depsipeptide
over 20 h, and cell viability was assessed by trypan blue exclusion
assays (Fig. 1a). The concentration of HDACi resulting in 70%
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cell death (IC70) was 0.5 M for vorinostat, 0.1 M for oxam-
flatin, and 3 nM for depsipeptide. All compounds induced
comparable histone H3 hyperacetylation at their respective IC70
concentrations (data not shown). Treatment of E-myc lym-
phoma cells with HDACi at their IC70 concentrations induced
plasmamembrane disruption, loss ofMOMP, caspase activation,
DNA fragmentation [supporting information (SI) Fig. 7], and
annexin V staining (data not shown), indicating that HDACi
induced apoptosis in E-myc lymphomas.
We next tested the sensitivity of E-myc lymphomas with
defined defects in apoptotic pathways that confer resistance to
anticancer drugs. The tumor-suppressor protein p53 plays a key
role in mediating apoptosis by various cytotoxic agents (13), and
hyperacetylation of p53 enhances the transcriptional activity of
p53 (14, 15), resulting in increased expression of p53 target genes
such as Noxa to initiate apoptosis (16). We tested the sensitivity
of E-myc/p53/ lymphomas to vorinostat. Apoptotic signaling
by HDACi was not impaired in the absence of p53 (Fig. 1b and
SI Fig. 8). E-myc/p53/ lymphomas were also sensitive to
oxamflatin and depsipeptide (data not shown) but are resistant
to the alkylating agent Etoposide (Fig. 1b).
Using human tumor cell lines, we demonstrated that apoptotic
activity of HDACi was inhibited by overexpression of Bcl-2 (3,
4). We developed E-myc/Bcl-2 lymphoma cells and found that
they were resistant to vorinostat-induced apoptosis (Fig. 1b and
SI Fig. 8). These cells did undergo a G1 cell cycle arrest (SI Fig.
8), with69% of cells in G1 after vorinostat treatment compared
with 41% of vehicle-treated cells in G1. Similar results were
seen after treatment of E-myc/Bcl-2 lymphomas with oxam-
flatin and depsipeptide (data not shown). G1 cell cycle arrest of
E-myc/Bcl-2 lymphomas after HDACi treatment is consistent
with the observed induction of CDKN1A encoding p21WAF1/CIP1
in all E-myc lymphomas that were studied (data not shown).
Vorinostat-induced acetylation of histone H3 was equivalent in
E-myc, E-myc/p53/, and E-myc/Bcl-2 lymphomas (SI
Fig. 9).
Vorinostat Has Antitumor Activity Against E-myc Lymphomas in
Vivo.We next tested the ability of vorinostat to induce apoptosis
in vivo and to prolong survival of lymphoma-bearing mice.
Vorinostat induced a marked accumulation of E-myc lympho-
mas displaying DNA fragmentation in vivo (Fig. 2a), comparable
to that seen with etoposide (Fig. 2a Inset). Similar to the in vitro
data, vorinostat induced loss of MOMP and increased caspase
activity in E-myc lymphomas in vivo (data not shown). Vori-
nostat-induced apoptosis of E-myc lymphoma cells in vivo was
further assessed by TUNEL assay (17). In contrast to untreated
controls, vorinostat-treatment resulted in a vast increase in
apoptotic cells (Fig. 2b Upper) and large numbers of shrunken
lymphoma cells displayed condensed chromatin (Fig. 2b Lower).
Lymphocytes from vorinostat-treated C57BL/6 mice did not
undergo apoptosis (Fig. 2c) indicating that vorinostat-induced
apoptosis was selective for lymphoma cells and resulted in a
decrease in E-myc lymphoma cells from the lymph node (Fig.
2a Lower).
The survival of vorinostat-treated mice was significantly ex-
tended compared with vehicle-treated mice (Fig. 2d; median
a
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Fig. 1. In vitro sensitivity of E-myc lymphomas to different HDACi. (a)
E-myc lymphomas were incubated with the indicated concentrations of
vorinostat (Left), oxamflatin (Center), or depsipeptide (Right) for 20 h. (b)
E-myc, E-myc/p53/, and E-myc/Bcl-2 lymphomas were incubated with
increasing concentrations of vorinostat (Left), and E-myc and E-myc/p53/
lymphomas were treated with increasing concentrations of Etoposide (Right)
for 20 h. Cell viability was assessed by trypan blue uptake. Error bars indicate
SEM of at least three independent experiments.
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Fig. 2. Vorinostat selectively kills E-myc lymphoma cells in vivo. (a) C57BL/6
mice bearing E-myc lymphomas were injected with vorinostat (200 mg/kg
i.p.) (Left) or 25 mg/kg i.p Etoposide (Inset), and lymphoma cells were har-
vested after the indicated time points. Apoptosis (sub-G1 population) was
measured by PI staining. (Right) The percentage of tumor cells in the lymph
node of C57BL/6 mice bearing E-myc lymphomas treated with vorinostat was
determined by FACS analysis. (b) TUNEL (Upper) and H&E (Lower) staining of
tissue sections from lymph nodes of mice bearing E-myc lymphomas treated
with vehicle (Left) or 200 mg/kg vorinostat (Right) for 12 h. (Scale bar: 10 m.)
(c) Apoptosis of splenocytes from vorinostat-treated or -irradiated mice
(-Irr) (3 Gy) was assessed by PI staining. Error bars representSEM from three
independent experiments. (d) E-myc lymphomas were transplanted into
C57BL/6 mice, and treatment with vorinostat or vehicle commenced once WBC
counts reached 13  103 per microliter or greater (day 10) and were termi-
nated on day 31. Kaplan–Meier survival curves of vehicle-treated mice (black
line) and vorinostat-treated mice (dashed line) are shown. (e) WBC counts
from mice transplanted with E-myc lymphomas at the commencement of
therapy (day 0) with either vehicle or vorinostat or after 7 days of treatment
(day  7) are shown. Error bars represent SEM. *, P  0.05.
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survival vehicle 18 days, median survival vorinostat 34 days,
P  0.0005) and vorinostat induced a statistically significant
reduction of WBC counts after 1 week of treatment (Fig. 2e).
Autopsy of vehicle-treated mice revealed disseminated disease
throughout the lymphoid system with enlarged lymph nodes and
splenomegaly. Vorinostat-treated mice autopsied at the same
time displayed no overt signs of lymphoma (SI Fig. 10). Similar
vorinostat-mediated effects on lymphoma survival,WBC counts,
and therapeutic outcome were observed by using two additional,
independently derived E-myc lymphomas (SI Fig. 11 a and b).
Although mice succumbed to disease after cessation of vorinos-
tat treatment, in vitro assays using lymphomas from relapsed
mice showed no evidence that these cells were less sensitive to
vorinostat than parental cells that had never been exposed to
vorinostat (data not shown).
Vorinostat Therapy Is p53-Independent but Abrogated by Overexpres-
sion of Bcl-2. E-myc/p53/ tumors were sensitive to vorinostat
in vivo (Fig. 3 a and b); however, these cells were relatively
resistant to the DNA-damaging agent etoposide (Fig. 3a Inset).
A robust therapeutic response was achieved by using vorinostat
against E-myc/p53/ lymphomas [Fig. 3c (median survival
vehicle 11.5 days, median survival vorinostat 28.5 days, P
0.0001) and SI Fig. 12 (n  three independently derived lym-
phomas analyzed] that was preceded by a significant decrease in
WBC counts to normal levels (Fig. 3d).
Consistent with our in vitro data (Fig. 1b and SI Fig. 8),
vorinostat was unable to kill Bcl-2 overexpressing E-myc
lymphomas in vivo (Fig. 3 e and f ) but did arrest cells in the G1
(Fig. 3g). The loss of vorinostat-induced apoptosis translated into
a dramatic reduction of therapeutic efficacy [Fig. 3h (median
survival vehicle 10 days, median survival vorinostat 13 days,
P  0.0001) and SI Fig. 13 (n  two independent lymphomas
analyzed], and vorinostat did not cause a decline in WBC counts
(Fig. 3i). Similar results were obtained by using E-myc lym-
phomas overexpressing Bcl-XL (SI Fig. 14). Taken together,
these data indicate that, in myc-driven murine lymphomas,
apoptosis mediated by the intrinsic apoptotic pathway is critical
for the therapeutic response to vorinostat.
Role of the Extrinsic Cell Death Pathway and Identification of the
BH3-Only Proteins Bim and Bid as Targets in Vorinostat-Mediated
Lymphoma Therapy. In acute myeloid leukemias tumor cell-
selective up-regulation of death receptors (i.e., DR5, Fas) and
their cognate ligands [i.e., tumor necrosis factor-related apopto-
sis-inducing ligand (TRAIL), Fas ligand (FasL)] are reported to
play an important role in the therapeutic response to HDACi
(18, 19). To evaluate the role of TRAIL in mediating the
therapeutic activity of vorinostat, we generated E-myc/
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Fig. 3. Vorinostat therapy is p53-independent but completely inhibited by overexpression of Bcl-2. C57BL/6 mice were transplanted with E-myc/p53/ (a–d)
or E-myc/Bcl-2 (e–i) lymphomas. Vorinostat-induced apoptosis was assessed by PI staining/flow cytometry (IVA assay) (a and e) and by TUNEL assay and
histological examination (b and f ) as in Fig. 2. Vorinostat-mediated therapeutic responses (c and h) and effects on WBC counts (d and i) were performed as in
Fig. 2. (a Inset) The percentage of sub-G1 E-myc/p53/ lymphomas after 12-h treatment with Etoposide (25 mg/kg i.p.) is shown. (c) Treatment of E-myc/p53/
lymphomas commenced on day 10 after tumor injection and terminated on day 30. Kaplan–Meier survival curves of vehicle-treated mice (black line) and
vorinostat-treated mice (dashed line) are shown. (g) The histograms show the cell cycle profiles of E-myc/Bcl-2 lymphomas harvested from the lymph nodes of
transplanted C57BL/6 mice after 12-h treatment with vehicle (Upper) or vorinostat (Lower). (h) Treatment of E-myc/Bcl-2 lymphomas commenced on day 6 after
tumor injection and terminated on day 13. Kaplan–Meier survival curves of vehicle-treated mice (black line) and vorinostat-treated mice (dashed line) are shown.
*, P  0.05; **, P  0.13.
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TRAIL/ lymphomas. These cells were sensitive to vorinostat-
induced apoptosis in vivo, and the therapeutic efficacy against
the E-myc/TRAIL/ lymphomas was similar to that seen
against E-myc and E-myc/p53/ tumors (SI Fig. 15).
The role of extrinsic apoptotic pathway in vorinostat-mediated
tumor cell death, was further evaluated in lymphoma cells that
overexpress the viral serpin CrmA, which effectively blocks
death receptor signaling through inhibition of caspase-8 and -10
(20). E-myc/CrmA lymphomas were sensitive to vorinostat in
vivo (Fig. 4 a and b) and displayed therapeutic responsiveness
[Fig. 4c (median survival vehicle  11.5 days, median survival
vorinostat  37 days, P  0.0001) and SI Fig. 16] and decreased
WBC counts (Fig. 4d) similar to that seen using E-myc,
E-myc/p53/, and E-myc/TRAIL/ lymphomas. Taken to-
gether, these data indicate that, in contrast to the reported role
of death receptor signaling in mediating HDACi-induced death
of myeloid leukemia cells (18, 19), there is no evidence to
support a role for this pathway in vorinostat-induced apoptosis
and therapy of c-myc-driven lymphomas.
To identify the molecular events in the intrinsic apoptotic
pathway necessary for vorinostat-mediated apoptosis of E-myc
lymphomas, we performed genotype-response analyses using
lymphomas lacking the proapoptotic BH3-only proteins Bid and
Bim, which can act as upstream inducers of Bcl-2-dependent
mitochondrial apoptosis (21). The proapoptotic BH3-only mol-
ecule Bid is activated upon HDACi treatment of cultured human
leukemia CCRF-CEM cells (3). Treatment of E-myc lympho-
mas with vorinostat in vivo resulted in cleavage of Bid in a tumor
cell-specific and time-dependent manner (SI Fig. 17a). We
generated E-myc/Bid/ lymphoma cells to assess the impor-
tance of Bid in mediating vorinostat-induced apoptosis. Bid
deficiency suppressed the in vivo apoptotic activity of vorinostat
(SI Fig. 17 b and c), and loss of Bid attenuated the therapeutic
effect of vorinostat with early tumor relapse evident while mice
were still receiving therapy (SI Fig. 17). Moreover, vorinostat
failed to significantly decrease WBC numbers in these mice.
When we administered vorinostat to E-myc lymphoma-
bearing mice, we noted that bim, but not bidmRNA was induced
specifically in lymphoma cells, but not in untransformed lym-
phocytes (Fig. 5a) and the BimL protein isoform was up-
regulated by vorinostat in vivo. (Fig. 5a Right). Bim deficiency
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Fig. 4. Antitumor efficacy of vorinostat is unaffected by inhibition of death
receptor signaling through CrmA overexpression. E-myc/CrmA lymphomas
were transplanted into C57BL/6 mice and vorinostat-induced apoptosis in vivo
(a and b), therapy (c), and depletion of WBC counts (d) were assessed as in Fig.
2. Treatment commenced on day 6 after tumor injection and terminated on
day 34. Kaplan–Meier survival curves of vehicle-treated mice (black line) and
vorinostat-treated mice (dashed line) are shown. *, P  0.05.
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Fig. 5. Bim is a previously unrecognized target for HDACi in vivo. (a)
Up-regulation of Bim mRNA and protein by vorinostat. (Left) Levels ofbimand
bidmRNA were measured by quantitative real-time PCR in the lymphoma cells
and in nontumor cells, respectively. Two independent sets of mice were
examined and relative induction of mRNA levels are shown for one represen-
tative cohort. (Right) E-myc lymphomas were transplanted into C57BL/6
mice, which were subsequently treated with 200 mg/kg vorinostat. Lymph
nodes were harvested after the indicated time points, and Western blotting
was performed by using an anti-murine Bim antibody. Blots were stripped and
reprobed with an anti-Hsp70 antibody to ensure equivalent protein loading.
E-myc/Bim/ lymphomas were transplanted into C57BL/6 mice, and vori-
nostat-induced apoptosis in vivo (b and c), therapy (d), and suppression of
WBC counts (e) were assessed as in Fig. 2. Treatment commenced on day 9 after
tumor injection and terminated on day 34. Kaplan-Meier survival curves of
vehicle-treated mice (black line) and vorinostat-treated mice (dashed line) are
shown. *, P  0.058.
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severely decreased responsiveness to vorinostat as shown by in
vivo apoptosis assay (IVA) and TUNEL analyses (Fig. 5 b and
c). In contrast, the apoptotic response to Etoposide was not
altered (compare Fig. 2a Inset with Fig. 5b Inset). Mice bearing
E-myc/Bim/ lymphomas relapsed early during vorinostat
therapy [Fig. 5d (median survival vehicle  11 days, median
survival vorinostat  17 days, P  0.0007) and SI Fig. 18 (n 
three independently derived lymphomas analyzed)] and WBC
counts were not significantly reduced (Fig. 5e). Taken together,
these data show that proapoptotic signaling by the BH3-only
proteins Bim and Bid plays an important role in vorinostat-
mediated lymphoma therapy.
In Vivo Apoptotic Response Predicts Therapeutic Outcome.We com-
pared therapeutic outcome with sensitivity to vorinostat-induced
apoptosis for independently derived lymphomas of multiple
genotypes. A statistically significant correlation (R  0.76 for
linear regression) was observed between ‘‘specific death’’ as
determined by in vivo apoptosis assays and ‘‘survival benefit’’
[median survival (vorinostat-treated mice)  median survival
(vehicle-treated mice)] (Fig. 6). Lymphomas with overexpres-
sion of Bcl-2, Bcl-XL, or deletion of Bid or Bim formed a
‘‘therapy-resistant’’ cluster (Fig. 6, blue box). In contrast, un-
modified E-myc lymphomas and those compound mutant
lymphomas with deactivated extrinsic apoptotic pathways or
deletion of p53 grouped together in a ‘‘therapy-sensitive’’ cluster
(Fig. 6, red box). Robust suppression of WBC counts after 1
week of vorinostat therapy was only observed in E-myc,
E-myc/p53/, E-myc/TRAIL/, and E-myc/CrmA lym-
phomas, but not in lymphomas with defects in apoptosis medi-
ated by the intrinsic pathway (SI Fig. 19a). Indeed, all but one
lymphoma of the resistant genotypes (E-myc/Bcl-2, E-myc/
Bcl-XL, E-myc Bid/, E-myc Bim/) fatally relapsed within
1 week after onset of treatment, whereas none of the other
genotypes did so, and contingency analysis revealed high statis-
tical significance (SI Fig. 19b).
Discussion
HDACi can elicit diverse biological responses such as induction
of cellular differentiation, suppression of cell proliferation,
apoptosis, inhibition of angiogenesis, and modulation of immune
responses (2). The molecular pathways of HDACi-induced apo-
ptosis in vivo are not fully elucidated. Herein, we used the
E-myc transgenic mouse model of B cell lymphoma to system-
atically assess genotype-response relationships in a series of
lymphomas with defined genetic alterations in apoptotic path-
ways. We found a direct link between HDACi-induced apoptosis
and therapeutic efficacy. Vorinostat engaged the intrinsic apo-
ptotic pathway in a p53-independent manner. The apoptotic and
therapeutic activities of vorinostat were attenuated in cells
devoid of the proapoptotic BH3-only Bcl-2 family proteins Bid
or Bim. The death receptor pathway was not required for the
apoptotic or therapeutic activities of the HDACi vorinostat.
Furthermore, our studies show that, for E-myc lymphomas, the
therapeutic efficacy of vorinostat could be predicted on the basis
of the short-term in vivo responsiveness of lymphoma cells to
vorinostat as determined by our IVA assay and reduction in
WBC numbers. Vorinostat induced equivalent histone hyper-
acetylation in resistant and sensitive E-myc lymphomas, indi-
cating that the inhibition of vorinostat-mediated apoptosis and
therapy occurs downstream of histone hyperacetylation.
We identified the BH3-only proteins Bid and Bim as impor-
tant regulators of vorinostat-mediated apoptosis and therapy.
Here, we report previously unrecognized evidence that vorinos-
tat treatment up-regulates Bim mRNA and protein in vivo, and
our results are in agreement with an in vitro study that showed
that decreasing expression of Bim by siRNA suppressed the
apoptotic effect of vorinostat (22). Bim expression can be
regulated by transcription factors such as Foxo3a (23) and E2F1
(22). Addition of HDACi augments the transcriptional activa-
tion Bim by these factors.
We and others have shown that Bid is cleaved and activated
in tumor cell lines treated with HDACi in vitro (3, 4, 6, 24), and
we demonstrate herein that Bid is cleaved in a tumor cell-
selective manner in vivo after administration of vorinostat. Bid
is clearly important for the apoptotic and therapeutic activity of
vorinostat. This effect appears to be selective for vorinostat as
E-myc/Bid/ lymphomas remain fully sensitive to other che-
motherapeutic drugs such as etoposide. We have yet to identify
the protease(s) responsible for vorinostat-induced cleavage and
activation of Bid. We have shown that the caspase inhibitor
zVAD-fmk, which can suppress vorinostat-induced cleavage of
poly(ADP-ribose) polymerase (PARP), does not affect this
process (3, 4). Studies with various transformed cells, including
our preliminary data using E-myc/Puma/ lymphoma cells
(data not shown), indicate that not all BH3-only proteins are
likely to be involved in the apoptotic response to vorinostat (3,
6, 7, 9, 24).
HDACi have shown promise in early-phase clinical trials for
the treatment of hematological malignancies, and, in a phase IIb
open-label study, 24% of cutaneous T cell lymphoma (CTCL)
patients who had failed conventional therapies had a complete
or partial response to vorinostat as a single agent (25). Vori-
nostat is the first HDACi to receive Food and Drug Adminis-
tration approval as an anticancer drug for the treatment of CTCL
(12). Our data provide insight into the molecular events that
underpin vorinostat-induced apoptosis and identify lesions
within specific apoptotic pathways that lead to resistance to
vorinostat. Specifically, overexpression of Bcl-2 or Bcl-XL or the
loss of expression of Bid or Bim abrogate the effects of vori-
nostat. Human leukemias and lymphomas commonly overex-
press prosurvival Bcl-2 proteins as do certain solid tumors (13).
In addition, the BH3-only proteins Bim and Bid show tumor-
suppressor function in certain contexts (26, 27), and inactivating
mutations or loss of expression in human cancer samples have
been reported (28–30). On the basis of our findings, the signif-
icance of the expression and/or functional status of prosurvival
Bcl-2 proteins and certain proapoptotic BH3-only proteins
Fig. 6. Apoptotic sensitivity to vorinostat in vivo correlates with therapeutic
outcome. Sensitivity of lymphomas in the IVA assay correlates with therapeu-
tic outcome. Specific cell death [(percent cell death after 12 h of vorinostat)
(percent cell death at 0 h)] was plotted against the therapeutic window
[(median survival vorinostat cohort) (median survival control cohort)]. Bcl-2-
and Bcl-XL-overexpressing Bid/ and Bim/ lymphomas show low in vivo
sensitivity to vorinostat, reduced responsiveness in therapy experiments, and
form a ‘‘resistance’’ cluster (blue box). E-myc, E-myc/p53/, E-myc/
TRAIL/, and E-myc/CrmA lymphomas were sensitive to vorinostat in vivo
and formed a sensitive cluster (red box). The color of the diamonds corre-
sponds to different genotypes, as outlined to the right. Statistical analysis:
Mean specific cell death-resistant cluster  5.9%; 95% confidence interval
(CI)  1.3–10.6%. Mean specific cell death in sensitive cluster  30.4%; 95%
CI  25.1–35.8; P  0.0001. Mean therapeutic window resistant cluster  5.1
days; 95% CI  3.8–6.3. Mean therapeutic window sensitive cluster  16.5
days; 95% CI  13.8–19.2; P  0.0001.
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across a range of hematological and solid tumors should be
studied in greater detail.
Materials and Methods
E-myc Lymphomas. Lymphomas were isolated from E-myc or
E-myc/p53/ transgenic mice (11). E-myc/Bcl-2, E-myc/
Bcl-XL, and E-myc/CrmA lymphomas were engineered by
retroviral transduction of freshly isolated lymphoma cells and
the generation of Bid/, Bim/, and TRAIL/ E-myc
lymphomas are detailed in SI Methods.
In Vitro Cell Death Analysis. E-myc lymphoma cells (2–5  105)
were incubated in the presence of the indicated compounds for
20 h, and cell viability was measured by trypan blue exclusion
assay (3) or propidium iodide (PI) (31) MOMP was analyzed by
using tetramethyl-rhodamine ethyl ester (TMRE) (31). Caspase
activity was measured as described in refs. 7 and 8. Cell cycle
analysis using PI staining was performed (4). IVA is detailed in
SI Methods.
Mice. For IVA and therapy studies, 6- to 8-week-old C57BL/6
mice were used. The Peter MacCallum Cancer Centre Animal
Ethics Committee approved all mouse protocols used in this
study. PCR-based genotyping and Western blot analysis were
used to validate lymphoma genotypes (data not shown).
Extraction of Histones and Western Blotting. Histone extracts and
whole-cell lysates were prepared as described in ref. 4. Proteins
were separated by SDS/10% polyacrylamide gel electrophoresis,
and Western blotting was performed (4).
Therapy Experiments.C57BL/6mice were injected i.v. with 5 105
E-myc lymphoma cells of the indicated genotypes. Peripheral
WBC counts were monitored, and therapy commenced when
counts exceeded 13  103 per microliter (Sysmex Hematology
Analyzer K-1000; Sysmex, Malberg, Germany). Vorinostat was
administered at 200 mg/kg i.p. for 7 days, followed by i.p.
vorinostat for 14–21 days at 150 mg/kg. Control mice received
the corresponding amount of DMSO. Cohorts consisted of 8–11
mice each and two to three independently derived lymphomas
per genotype. Peripheral WBC counts and body weights were
recorded weekly. For analysis of therapeutic efficacy, tumor-
induced mortality ‘‘events’’ were recorded. Histology and
TUNEL staining were performed as detailed in the SI Methods.
Statistics. Kaplan–Meier analysis was performed and compari-
sons were made using the log-rank (Mantel–Cox) test (MedCalc
software, version 8.0.2.0; MedCalc, Mariakerke, Belgium). P
values were calculated by using a two-way t test. Ninety-five-
percent confidence intervals were calculated by using MedCalc
software. Contingency analysis was performed by using the
StatPages online tool.
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